Breaking News
Get 50% Off 0
Join +750K new investors every month who copy stock picks from billionaire's portfolios Sign Up Free
Close

Novo Nordisk A/S (NVO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Novo Nordisk ADR's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
140.80 +0.43    +0.31%
05:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
140.80
0.00
0.00%
08:33:34 - Real-time Data
  • Volume: 2,636,779
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 139.78 - 141.71
Type:  Equity
Market:  United States
Novo Nordisk ADR 140.80 +0.43 +0.31%

NVO Financial Summary

 
A brief financial summary of Novo Nordisk A/S as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Novo Nordisk A/S reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was DKK 58,731 million compared to DKK 45,566 million a year ago. Net income was DKK 22,478 million compared to DKK 14,405 million a year ago.For the nine months, sales was DKK 166,398 million compared to DKK 128,862 million a year ago. Net income was DKK 61,720 million compared to DKK 41,933 million a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

NVO Income Statement

Gross margin TTM 84.65%
Operating margin TTM 45.38%
Net Profit margin TTM 36.55%
Return on Investment TTM 76.69%
 Total Revenue  Net Income
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Revenue 65349 65863 58731 54300
Gross Profit 55433 55849 49018 46444
Operating Income 31846 28180 26913 23888
Net Income 25407 21963 22478 19428

NVO Balance Sheet

Quick Ratio MRQ 0.4
Current Ratio MRQ 0.7
LT Debt to Equity MRQ 16.95%
Total Debt to Equity MRQ 27.22%
 Total Assets  Total Liabilities
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Assets 298921 314486 300101 280753
Total Liabilities 200010 207925 207110 190280
Total Equity 98911 106561 92991 90473

NVO Cash Flow Statement

Cash Flow/Share TTM 20.93
Revenue/Share TTM 54.74
Operating Cash Flow  8.64%
 Cash  Net Change in Cash
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 14314 9551 40966 28577
Cash From Investing Activities 3956 -14717 -13243 -9285
Cash From Financing Activities -26382 -10116 -19832 -12589
Net Change in Cash -8068 -15491 8309 6638
* In Millions of DKK (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NVO Comments

Write your thoughts about Novo Nordisk A/S
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Mac Dre
Mac Dre Oct 14, 2023 6:40
Saved. See Saved Items.
This comment has already been saved in your Saved Items
we're going to the moon 🌙 🌚 ✨️
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email